1. Regulatory Framework
The Pharmacopoeial Standards for Ayurvedic Drugs are governed under:
- Drugs and Cosmetics Act, 1940
- Drugs and Cosmetics Rules, 1945 (Rule 160–170 & Schedule T)
- Formulated and published by the Pharmacopoeia Commission for Indian Medicine and Homoeopathy (PCIM&H), an autonomous body under the Ministry of AYUSH.
- These standards are legally binding for all manufacturers of Ayurveda, Siddha, Unani, and Homoeopathy (ASU&H) drugs in India.
2. Objective of Pharmacopoeial Standards
The purpose of these guidelines is to:
- Ensure identity, purity, quality, and strength of Ayurvedic medicines.
- Guarantee safety for human consumption.
- Provide uniformity in dosage forms and preparation methods.
- Promote international acceptability of Indian traditional medicines.
3. Key Documents Published by Ministry of AYUSH / PCIM&H
- Ayurvedic Pharmacopoeia of India (API) – Defines standards for raw materials and formulations.
- Part I: Single Drugs (herbal, mineral, metal origin)
- Part II: Compound Formulations
- Ayurvedic Formulary of India (AFI) – Lists standardized classical formulations.
- General Guidelines for Drug Development of Ayurvedic Formulations – Issued by CCRAS for safety, efficacy, and clinical evaluation.
- GMP Guidelines (Schedule T) – Good Manufacturing Practices specific to Ayurvedic manufacturing units.
4. Parameters for Ensuring Purity, Safety, and Dosage
A. Identification & Authentication
- Botanical and scientific names must match official monographs in the Ayurvedic Pharmacopoeia of India.
- Raw materials are verified through:
- Macroscopic & Microscopic examination
- Chromatographic profiling (TLC/HPTLC)
- Chemical fingerprinting
B. Purity Standards
Each monograph specifies limits for:
- Foreign matter: ≤2%
- Moisture content: ≤12%
- Total ash: ≤5–10% depending on plant type
- Acid-insoluble ash: ≤1–2%
- Alcohol and water-soluble extractive values: Defined range
- Heavy metals:
- Lead (Pb) ≤10 ppm
- Arsenic (As) ≤3 ppm
- Cadmium (Cd) ≤0.3 ppm
- Mercury (Hg) ≤1 ppm
- Pesticide residues: Within WHO/FAO permissible limits
- Aflatoxin limits:
- Total aflatoxins ≤30 ppb
- Aflatoxin B₁ ≤10 ppb
- Microbial load:
- Total bacterial count ≤10⁵ CFU/g
- Total fungal count ≤10³ CFU/g
- E. coli, Salmonella, Staphylococcus aureus – absent
C. Safety Evaluation
- Toxicity Studies: Acute, sub-acute, and chronic toxicity tests must be performed for new or proprietary Ayurvedic formulations (CCRAS guideline).
- Metallic/Mineral Preparations (Bhasma):
- Must undergo Shodhana (purification) and Marana (incineration) as per classical texts.
- Must be tested for particle size, bioavailability, and absence of free toxic metals.
- Clinical Safety: Required for non-classical or modified formulations.
D. Strength and Potency
- Defined through marker compound assays and physico-chemical constants (like extractive values, pH, viscosity).
- Shelf-life and potency determined by stability testing (as per Rule 161B of the Drugs & Cosmetics Rules).
E. Dosage Standards
- Dosage forms include Churna, Avaleha, Vati, Taila, Asava-Arishta, Bhasma, etc.
- Dosages are standardized in Ayurvedic Formulary of India (AFI) — based on:
- Age, body weight, dosha condition, and disease state.
- Example:
- Churna (powder): 3–5 g twice daily
- Kwatha (decoction): 50–100 ml twice daily
- Vati (tablet): 1–2 tablets twice daily
- Asava/Arishta: 10–20 ml twice daily after meals
5. Good Manufacturing Practices (GMP – Schedule T)
To maintain consistency and safety:
- Use authentic raw materials verified with pharmacopoeial standards.
- Maintain hygienic processing, calibrated equipment, and trained staff.
- Conduct in-process quality checks and batch record documentation.
- Maintain stability data, labeling accuracy, and storage conditions.
6. Laboratory Testing and Certification
Testing must be done at:
- State Drug Testing Laboratories (ASU&H) or
- Approved private labs recognized by PCIM&H.
Each drug is tested for:
- Identity
- Purity
- Strength
- Safety parameters
7. Institutional Framework Under Ministry of AYUSH
- Pharmacopoeia Commission for Indian Medicine and Homoeopathy (PCIM&H), Ghaziabad – Formulation and publication of pharmacopoeial standards.
- Central Council for Research in Ayurvedic Sciences (CCRAS) – Research and safety validation.
- National Institute of Ayurveda (NIA), Jaipur – Academic and technical input.
- IMPCL (Indian Medicines Pharmaceutical Corporation Ltd.) – Produces pharmacopoeial-grade medicines.
8. Legal Enforcement
- Only Ayurvedic drugs conforming to Pharmacopoeial Standards can be licensed and marketed in India.
- Non-compliance can lead to classification as “Misbranded” or “Spurious” under Sections 33E–33EE of the Drugs & Cosmetics Act.
9. Summary Table
| Aspect | Guideline/Authority | Ensures |
|---|---|---|
| Identity | Ayurvedic Pharmacopoeia of India | Correct plant/drug |
| Purity | PCIM&H / GMP Schedule T | Free from contaminants |
| Safety | CCRAS Guidelines / Toxicity Tests | Human safety |
| Strength | Monograph assays | Efficacy and consistency |
| Dosage | Ayurvedic Formulary of India | Safe administration |
| Manufacturing | GMP (Schedule T) | Quality and hygiene |
| Licensing | State Licensing Authority | Legal compliance |
Reference Links (Official)
- Pharmacopoeia Commission for Indian Medicine & Homoeopathy (PCIM&H)
- Ayurvedic Pharmacopoeia of India (API)
- Ministry of AYUSH – Drugs & Cosmetics Act & Rules
- CCRAS – General Guidelines for Drug Development of Ayurvedic Formulations